Integrated Drug Discovery
Axxam integrated drug discovery model
Accelerate and de-risk early drug discovery through an integrated target-to-lead workflow combining biology, screening, chemistry, and AI-enabled analytics.
NAMs and early de-risking
Integrate human-relevant New Approach Methodologies (NAMs) early in discovery to strengthen biological relevance, identify potential liabilities, and support more informed development decisions.
Wet labs enabling AI drug discovery
Enable AI-driven drug discovery through integrated experimental validation, advanced assays, and translational workflows powered by biological expertise.
RNA biology and beyond
Advance RNA-based drug discovery through integrated molecular biology, assay development, and high-throughput screening technologies.
Agrochemical discovery
Accelerate the discovery of next-generation agrochemicals through advanced target biology, tailored in vitro assays, and screening technologies.
Integrated drug discovery at Axxam is delivered through DiscoveryMAXX, our fully coordinated target-to-lead platform designed to translate biological insight and AI-driven predictions into experimentally validated drug candidates. DiscoveryMAXX combines multidisciplinary scientific expertise with advanced assay technologies to ensure continuity, data quality, and efficient decision making across early discovery.
A key strength is the wet-lab validation of AI-enabled predictions, translating in silico target, pathway, and compound insights into experimental evidence through tailored biochemical and cellular assays.
Our integrated approach spans target assessment, hit and lead discovery, RNA biology and novel target classes, NAMs and early de-risking, while extending our discovery expertise beyond pharma to agrochemical discovery.